417 related articles for article (PubMed ID: 35174556)
1. Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate-to-severe plaque psoriasis.
Gooderham M; Pinter A; Ferris LK; Warren RB; Zhan T; Zeng J; Soliman AM; Kaufmann C; Kaplan B; Photowala H; Strober B
J Eur Acad Dermatol Venereol; 2022 Jun; 36(6):855-865. PubMed ID: 35174556
[TBL] [Abstract][Full Text] [Related]
2. Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials.
Augustin M; Lambert J; Zema C; Thompson EHZ; Yang M; Wu EQ; Garcia-Horton V; Geng Z; Valdes JM; Joshi A; Gordon KB
JAMA Dermatol; 2020 Dec; 156(12):1344-1353. PubMed ID: 33052382
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Gordon KB; Strober B; Lebwohl M; Augustin M; Blauvelt A; Poulin Y; Papp KA; Sofen H; Puig L; Foley P; Ohtsuki M; Flack M; Geng Z; Gu Y; Valdes JM; Thompson EHZ; Bachelez H
Lancet; 2018 Aug; 392(10148):650-661. PubMed ID: 30097359
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies.
Strober B; Menter A; Leonardi C; Gordon K; Lambert J; Puig L; Photowala H; Longcore M; Zhan T; Foley P
J Eur Acad Dermatol Venereol; 2020 Dec; 34(12):2830-2838. PubMed ID: 32320088
[TBL] [Abstract][Full Text] [Related]
5. Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders.
Strober B; Armstrong A; Rubant S; Patel M; Wu T; Photowala H; Crowley J
J Dermatolog Treat; 2022 Nov; 33(7):2991-2996. PubMed ID: 35839335
[TBL] [Abstract][Full Text] [Related]
6. Risankizumab vs. ustekinumab for plaque psoriasis: a critical appraisal.
Al-Janabi A; Jabbar-Lopez ZK; Griffiths CEM; Yiu ZZN
Br J Dermatol; 2019 Jun; 180(6):1348-1351. PubMed ID: 30632140
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up.
Papp KA; Lebwohl MG; Puig L; Ohtsuki M; Beissert S; Zeng J; Rubant S; Sinvhal R; Zhao Y; Soliman AM; Alperovich G; Leonardi C
Br J Dermatol; 2021 Dec; 185(6):1135-1145. PubMed ID: 34157132
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up.
Papp KA; Blauvelt A; Puig L; Ohtsuki M; Beissert S; Gooderham M; Amin AZ; Liu J; Wu T; Azam T; Stakias V; Espaillat R; Sinvhal R; Soliman AM; Pang Y; Chen MM; Lebwohl MG
J Am Acad Dermatol; 2023 Dec; 89(6):1149-1158. PubMed ID: 37553030
[TBL] [Abstract][Full Text] [Related]
9. Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials.
Kokolakis G; Warren RB; Strober B; Blauvelt A; Puig L; Morita A; Gooderham M; Körber A; Vanvoorden V; Wang M; de Cuyper D; Madden C; Nunez Gomez N; Lebwohl M
Br J Dermatol; 2023 Feb; 188(3):330-340. PubMed ID: 36751950
[TBL] [Abstract][Full Text] [Related]
10. Risankizumab: A Review in Moderate to Severe Plaque Psoriasis.
Blair HA
Drugs; 2020 Aug; 80(12):1235-1245. PubMed ID: 32632826
[TBL] [Abstract][Full Text] [Related]
11. The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients.
Abrouk M; Nakamura M; Zhu TH; Farahnik B; Koo J; Bhutani T
J Dermatolog Treat; 2017 Sep; 28(6):488-491. PubMed ID: 28042711
[TBL] [Abstract][Full Text] [Related]
12. Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse).
Stein Gold LF; Bagel J; Tyring SK; Hong HC; Pavlovsky L; Vender R; Pinter A; Reich A; Drogaris L; Wu T; Patel M; Soliman AM; Photowala H; Stakias V; Richter S; Papp KA
Br J Dermatol; 2023 Oct; 189(5):540-552. PubMed ID: 37488811
[TBL] [Abstract][Full Text] [Related]
13. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial.
Lebwohl M; Papp K; Han C; Schenkel B; Yeilding N; Wang Y; Krueger GG
Br J Dermatol; 2010 Jan; 162(1):137-46. PubMed ID: 19903183
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of long-term risankizumab treatment for moderate-to-severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial).
Strober B; Bachelez H; Crowley J; Elewski BE; Gooderham M; Menter A; Strohal R; Chen MM; Wu T; Zhan T; Photowala H; Armstrong A
J Eur Acad Dermatol Venereol; 2024 May; 38(5):864-872. PubMed ID: 38179809
[TBL] [Abstract][Full Text] [Related]
15. Absolute and relative psoriasis area and severity index (PASI) treatment goals and their association with health-related quality of life.
Gerdes S; Körber A; Biermann M; Karnthaler C; Reinhardt M
J Dermatolog Treat; 2020 Aug; 31(5):470-475. PubMed ID: 32202943
[No Abstract] [Full Text] [Related]
16. Deterioration of Health-Related Quality of Life After Withdrawal of Risankizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: A Machine Learning Predictive Model.
Papp KA; Soliman AM; Done N; Carley C; Lemus Wirtz E; Puig L
Dermatol Ther (Heidelb); 2021 Aug; 11(4):1291-1304. PubMed ID: 34019229
[TBL] [Abstract][Full Text] [Related]
17. Impact of PASI response on work productivity and the effect of risankizumab on indirect costs using machine learning in patients with moderate-to-severe psoriasis.
Lebwohl M; Soliman AM; Yang H; Wang J; Freimark J; Puig L
J Dermatolog Treat; 2022 Jun; 33(4):2094-2101. PubMed ID: 33899655
[TBL] [Abstract][Full Text] [Related]
18. Early Treatment Targets for Predicting Long-term Dermatology Life Quality Index Response in Patients with Moderate-to-Severe Plaque Psoriasis: A
Puig L; Zhu B; Burge R; Shrom D; Dong Y; Shen W; Mallbris L; Reich K
J Clin Aesthet Dermatol; 2020 Oct; 13(10):18-22. PubMed ID: 33584952
[No Abstract] [Full Text] [Related]
19. Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL).
Lacour JP; Bewley A; Hammond E; Hansen JB; Horne L; Paul C; Reich K; Seneschal J; De Simone C; Sohrt A; Augustin M; Pellacani G
Dermatol Ther (Heidelb); 2020 Oct; 10(5):1099-1109. PubMed ID: 32761560
[TBL] [Abstract][Full Text] [Related]
20. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.
Revicki DA; Willian MK; Menter A; Saurat JH; Harnam N; Kaul M
Dermatology; 2008; 216(3):260-70. PubMed ID: 18187944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]